Farhad Farzaliyev1, Alexander Touma2, Georg Taeger3, Hans-Ulrich Steinau2, Jendrik Hardes3, Arne Streitbürger3, Lars Erik Podleska3. 1. Department of General, Visceral and Transplantation Surgery, Division of Plastic and Reconstructive Surgery, University Hospital Essen, University Essen-Duisburg, Hufelandstr.55, 45147, Essen, Germany. farhad.farzaliyev@uk-essen.de. 2. Department of General, Visceral and Transplantation Surgery, Division of Plastic and Reconstructive Surgery, University Hospital Essen, University Essen-Duisburg, Hufelandstr.55, 45147, Essen, Germany. 3. Department of Tumor Orthopedics and Sarcoma Surgery, University Hospital Essen, Essen, Germany.
Abstract
BACKGROUND: This novel study compared the use of tumor necrosis factor (TNF)-alpha and melphalan-based isolated limb perfusion (TM-ILP) to the standard treatment of locally recurrent soft tissue extremity sarcoma. The aim was to assess whether TM-ILP positively influences the recurrence-free survival of locally recurrent high-grade soft tissue sarcoma (STS) of the extremities. METHODS: We retrospectively analyzed our clinical database for patients with STS. Variables were analyzed using chi-square test or Mann-Whitney rank-sum test. Furthermore, Kaplan-Meier survival plots were calculated and a proportional hazard regression model was developed. RESULTS: Out of 448 patients with extraabdominal STS treated between August 2012 and December 2015, 52 cases involving 47 patients had locally recurrent STS. Twenty-eight of these patients were treated with TM-ILP prior to surgical resection (TM-ILP-group), and 24 were treated with standard therapy (without TM-ILP). The 3-year recurrence-free survival for the TM-ILP-group was estimated at 75% (95% confidence interval (CI), 71.5-78.5). Local recurrence-free survival in the standard group was significantly lower (LRFS: 43.4%, 95% CI 38.7-48.1, p = 0.026). Multivariable analysis revealed resection with negative margins, lower number of previous recurrences, and TM-ILP as positive predictors for recurrence-free survival. CONCLUSIONS: TM-ILP and consecutive resection of residual tumor with negative resection margins significantly improves local recurrence-free survival for patients with a first local recurrence of high-grade STS in the extremities.
BACKGROUND: This novel study compared the use of tumor necrosis factor (TNF)-alpha and melphalan-based isolated limb perfusion (TM-ILP) to the standard treatment of locally recurrent soft tissue extremity sarcoma. The aim was to assess whether TM-ILP positively influences the recurrence-free survival of locally recurrent high-grade soft tissue sarcoma (STS) of the extremities. METHODS: We retrospectively analyzed our clinical database for patients with STS. Variables were analyzed using chi-square test or Mann-Whitney rank-sum test. Furthermore, Kaplan-Meier survival plots were calculated and a proportional hazard regression model was developed. RESULTS: Out of 448 patients with extraabdominal STS treated between August 2012 and December 2015, 52 cases involving 47 patients had locally recurrent STS. Twenty-eight of these patients were treated with TM-ILP prior to surgical resection (TM-ILP-group), and 24 were treated with standard therapy (without TM-ILP). The 3-year recurrence-free survival for the TM-ILP-group was estimated at 75% (95% confidence interval (CI), 71.5-78.5). Local recurrence-free survival in the standard group was significantly lower (LRFS: 43.4%, 95% CI 38.7-48.1, p = 0.026). Multivariable analysis revealed resection with negative margins, lower number of previous recurrences, and TM-ILP as positive predictors for recurrence-free survival. CONCLUSIONS:TM-ILP and consecutive resection of residual tumor with negative resection margins significantly improves local recurrence-free survival for patients with a first local recurrence of high-grade STS in the extremities.
Authors: E M Noorda; B C Vrouenraets; O E Nieweg; A N van Geel; A M M Eggermont; B B R Kroon Journal: Eur J Surg Oncol Date: 2006-01-18 Impact factor: 4.424
Authors: Colleen I Dickie; Anthony M Griffin; Amy L Parent; Peter W M Chung; Charles N Catton; Jon Svensson; Peter C Ferguson; Jay S Wunder; Robert S Bell; Michael B Sharpe; Brian O'Sullivan Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: Sylvie Bonvalot; Françoise Rimareix; Sylvain Causeret; Cécile Le Péchoux; Bérénice Boulet; Philippe Terrier; Axel Le Cesne; Jane Muret Journal: Ann Surg Oncol Date: 2009-10-15 Impact factor: 5.344
Authors: Daniel J Indelicato; Kenyon Meadows; Charles P Gibbs; Christopher G Morris; Mark T Scarborough; Robert A Zlotecki Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-15 Impact factor: 7.038